This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by University Hospital, Tours.
Recruitment status was:  Recruiting
Information provided by:
University Hospital, Tours Identifier:
First received: November 2, 2005
Last updated: November 21, 2007
Last verified: November 2007

This study intends to assess the ability of contrast-enhanced ultrasound in the detection of benign and malignant ovarian masses compared to unenhanced ultrasound.

By using an intravascular contrast agent, this noninvasive and feasible imaging technique will allow the investigators to define specific microcirculation patterns in 100 women with ovarian lesions.

The intravascular contrast agent properties will be compared between benign and malignant adnexal masses.

The final purpose of this ultrasonography is to allow the early detection of tumors and to improve the characterization between benign and malignant lesions.

Condition Intervention
Ovarian Tumor Procedure: Contrast-enhanced ultrasound

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

Resource links provided by NLM:

Further study details as provided by University Hospital, Tours:

Primary Outcome Measures:
  • From contrast-enhanced ultrasound: Enhancement parameters derived from time-intensity curves: time-to-peak, enhancement ratio, washout-time [ Time Frame: inclusion period ]

Secondary Outcome Measures:
  • Histology assessments: microvessel density assessments and histological diagnosis [ Time Frame: inclusion period ]

Estimated Enrollment: 100
Study Start Date: September 2002
Estimated Study Completion Date: February 2009
Intervention Details:
    Procedure: Contrast-enhanced ultrasound
    Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
Detailed Description:

SonoVue (Sulphur hexafluoride microbubbles) is a microbubbles preparation that is stable, resistant to pressure and specifically designed to be used as a contrast agent for ultrasound imaging.

Study design : one contrast-enhanced ultrasonography is proposed before any surgery to patients with ovarian mass.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Patient with adnexal mass detected by ultrasound
  • Any programmed surgery

Exclusion Criteria:

  • Any contraindication to surgery
  • Injection of another contrast agent within 24 hours before the study examination
  • Pregnancy, breastfeeding
  • Patient known to have a coronary syndrome
  • Unstable angina and myocardial infarction
  • Acute cardiac failure, Class III/IV cardiac failure
  • Severe rhythm disorders
  • Acute endocarditis
  • Prosthetic valves
  • Patient previously having received an investigational drug within 30 days prior to admission into this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00248820

Contact: Henri Marret, PR (33) 0 47 47 82 59

University Hospital of Tours Recruiting
Tours, France, 37044
Contact: Henri Marret, PR    (33) 0 47 47 82 59   
Sub-Investigator: François Tranquart, PR         
Sponsors and Collaborators
University Hospital, Tours
Principal Investigator: Henri Marret, PR Service de Gynécologie Obstétrique - Centre Olympe de Gouges CHRU Tours
Study Director: François Tranquart, PR Centre d'Innovation Technologique - CHRU Tours
  More Information

Publications: Identifier: NCT00248820     History of Changes
Other Study ID Numbers: CT02-OV
Study First Received: November 2, 2005
Last Updated: November 21, 2007

Keywords provided by University Hospital, Tours:
Contrast-enhanced Ultrasound
Ultrasound Contrast agent, microbubbles
Ovarian tumor

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders processed this record on September 21, 2017